Abstract: Disclosed is a method for producing an aromatic compound represented by the general formula (2) below, which is characterized in that a compound represented by the general formula (1) below is reacted with a sulfur compound (at least one member selected from the group consisting of sulfur, hydrogen sulfide, metal hydrosulfides and metal sulfides) or a selenium compound. (In the formula (1), R1 represents a hydrogen atom, a halogen atom, a hydroxyl group, a cyano group, a nitro group, an ester group, an optionally substituted alkyl group having 1-18 carbon atoms or the like; R2 represents a halogen atom; R3 represents a hydrogen atom, C?C—R1 or R2; and n represents an integer of 0-4. When n is not less than 2, R3's may be the same as or different from each other.) (In the formula (2), R1, R3 and n are as defined in the formula (1); and X represents a sulfur atom or a selenium atom.

Abstract: A thin-film transistor comprises a semiconducting layer comprising a semiconducting material selected from Formula (I) or (II): wherein X, R1, R2, R3, R4, R5 a, b, and n are as described herein. Semiconducting compositions of Formula (I) or (II) are also described.

Abstract: The present invention provides organoselenium compounds comprising dibenzoselenophene, benzo[b]selenophene or benzo[c]selenophene and their uses in organic light emitting devices.

Abstract: A class of compounds commonly containing a trialkylammonium group have been synthesized and characterized as anticancer compounds. They can be used alone or in combination with other therapies to treat cancer and other cell proliferative diseases. Representative compounds of this class, N,N-diethyl-N-methyl-2-[(9-oxo-9H-thioxanthen-2-yl)methoxy]ethanaminium iodide and N,N-diethyl-N-allyl-3-(2-methyl-9H-thioxanthen-9-ylidene)-propane-1-aminium bromide, were shown in various tumor models to decrease tumor volume, enhance the effects of other chemotherapeutic agents including cisplatin, reduce chemotherapy-induced loss of body weight, and increase survival of animals co-treated with toxic amounts of cisplatin. These compounds had even greater effects on tumor volume, body weight, and survival when administered together with the human protein placental alkaline phosphatase.

Abstract: Disclosed is a field-effect transistor characterized by using a compound represented by the formula (1) below as a semiconductor material. (In the formula (1), X1 and X2 independently represent a sulfur atom, a selenium atom or a tellurium atom; and R1 and R2 independently represent an unsubstituted or halogeno-substituted C1-C36 aliphatic hydrocarbon group.

Abstract: Compounds of formula (I) or pharmaceutically acceptable salts thereof, are agonists of GPR119 and are useful for the treatment of diabetes and as peripheral regulators of satiety, e.g. for the treatment of obesity and metabolic syndrome.

Abstract: The present invention relates to a compound represented by the formula (I), a salt thereof, an N-oxide form thereof, a solvate thereof, or a prodrug thereof, and a medicament containing the same. The compound represented by the formula (I) has an ability to bind to an S1P receptor (particularly, EDG-1, EDG-6, and/or EDG-8) and is useful for preventing and/or treating for rejection to transplantation, graft-versus-host disease, autoimmune diseases, allergic diseases, neurodegenerating diseases, and the like. wherein all symbols are described in the specification.

Abstract: The invention pertains to field of organic chemistry, medicine, pharmacology, foods and cosmetics industry, particularly, to manufacturing technology of selenoxanthenes; the invention may be used in manufacturing of food supplements, pharmaceutical and cosmetic products, having bioactive properties, of a wide spectrum of activity. The proposed compound is the ?-crystalline form of 9-phenyl-symmetrical-octahydroselenoxanthene with exhibits antioxidant, detoxifying, immunomodulating, anti-atherogenic, anti-sclerotic, anabolic and hypolipidemic properties, and has the following structural formula: Its powder X-ray diffractogram (obtained from a Cu-K X-ray source) has characteristic diffractions in degrees of the diffraction angle 2theta as 6.0, 12.0, 15.0, 17.0, 19.0, 20.0, 21.5, 21.7, 20.9, 25.0, 27.0, 28.0, 29.0, 37.0; the melting point of 96.8° C. The crystalline form of the respective 9-R-symmetrical-selenoxantene product is obtained by crystallization from a weakly polar or a non-polar solvent.

Abstract: A heterocyclic fused selenophenes and a method of making a heterocyclic fused selenophenes of formula (1): wherein X is S or Se, Y is S or Se, wherein one or both of X and Y is Se, R is a substituent group. The monomer being capable of polymerization to form an electrically conductive polymer or oligomer.

Abstract: The invention relates to an aqueous solution containing at least one species selected from the group consisting of a 1:1 molar complex of TeO2 with a moiety of formula (A) and ammonium salts thereof: HO—X—OH (A); where X is an optionally substituted divalent saturated hydrocarbon group containing 2-8 carbon atoms in the chain connecting the two OH groups; and its use for stimulating cells to produce cytokines and for treating mammalian diseases and conditions responsive to increased production of cytokines. The complex may be used also for treating mammalian cancer which is not responsive to increased production of cytokines.

Abstract: The present disclosure is directed, in part, to compounds and methods for imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging.

Abstract: A heterocyclic fused selenophenes and a method of making a heterocyclic fused selenophenes of formula (1): wherein X is S or Se, Y is S or Se, wherein one or both of X and Y is Se, R is a substituent group. The monomer being capable of polymerization to form an electrically conductive polymer or oligomer.

Abstract: Monomeric, oligomeric and polymeric electrically conductive compounds and methods of making the compounds having a repeating unit having formula P1, as follows: where X is S or Se, Y is S or Se, wherein one or both of X and Y is Se, R is a substituent group capable of bonding to the ring structure. R may include hydrogen or isotopes thereof, hydroxyl, alkyl, including C1 to C20 primary, secondary or tertiary alkyl groups, arylalkyl, alkenyl, perfluoroalkyl, perfluororaryl, aryl, alkoxy, cycloalkyl, cycloalkenyl, alkanoyl, alkylthio, aryloxy, alkylthioalkyl, alkynyl, alkylaryl, arylalkyl, amido, alkylsulfinyl, alkoxyalkyl, alkylsulfonyl, aryl, arylamino, diarylamino, alkylamino, dialkylamino, arylarylamino, arylthio, heteroaryl, arylsulfinyl, alkoxycarbonyl, arylsulfonyl, carboxyl, halogen, nitro, cyano, sulfonic acid, or alkyl or phenyl substituted with one or more sulfonic acid, phosphoric acid, carboxylic acid, halo, amino, nitro, hydroxyl, cyano or epoxy moieties.

Abstract: The object of the present invention is to provide a composition for conductive materials from which a conductive layer having a high carrier transport ability can be made, a conductive material formed of the composition and having a high carrier transport ability, a conductive layer formed using the conductive material as a main material, an electronic device provided with the conductive layer and having high reliability, and electronic equipment provided with the electronic device.

Abstract: The invention relates to a novel method for the synthesis of N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide.

Abstract: It is intended to provide novel labeling reagents characterized by having a group capable of binding to a substance to be labeled (for example, a biological substance, a physiologically active substance, etc.), easily forming a complex together with a rare earth ion, the complex being stable in an aqueous solution, and having a sufficient fluorescence intensity and a long fluorescence life time regardless of buffer types; complexes composed of the above labeling reagent with a rare earth ion; fluorescence labels containing the above complex; a fluorescence assay method using the above fluorescent label; etc. Namely, labeling reagents comprising a compound having a 2,2?:6?,2?-tripyridine skeleton or a 2,6-dipyrazolopyridine skeleton and having a group capable of binding to a substance to be labeled (for example, a biological substance, a physiologically active substance, etc.

Abstract: A process for making a compound of formula (I), which is useful as an intermediate to compounds which activate glucokinase, is described, (wherein P1, R1 and R2 are as defined in the description).

Abstract: A method of making an oxochlorin comprises the steps of oxidizing a chlorin to produce a mixture of hydronchlorin and oxochlorin, and then oxidizing the hydroxychlorin in said mixture, preferably with DDQ, to produce a mixture consisting essentially of oxochlorin. The step of oxidizing a chlorin is carried out by exposing the chlorin to alumina, typically in the presence of an oxidizing agent such as air or alumina. The oxidizing steps may be carried out in an organic solvent such as toluene. The chlorin is preferably a C-methylated chlorin, and is preferably metalated.

Abstract: The present invention relates to improved covalent coupling of two or more entities such as biomolecules, polymer compositions, organic/inorganic molecules/materials, and the like, including their combinations, through one or more novel reactive groups attached to linker groups of 2-1000 atoms length. The present invention also contemplates the use of bifunctional bridge molecules to link two or more entities, wherein the functional groups of the bridge molecules are the novel reactive groups of the present invention.

Abstract: The present invention describes new types of material mixtures composed of at least two substances, one serving as a matrix material and the other being an emission material capable of emission, the latter comprising at least one element of atomic number greater than 20, and the use thereof in organic electronic components such as electroluminescent elements and displays.

Abstract: A compound containing an alkylene selenocyanate or an alkylene isoselenocyanate moiety effective to prevent the occurrence or progression of cancer or a precancerous condition. The compound can be provided and administered in the form of a pharmaceutical composition, a cosmetic, a food additive, supplement, or the like. Methods for synthesis and use of the chemopreventive compound of the invention are also provided.

Abstract: A method of making a compound of the formula shown below is disclosed: wherein Z is Se or S; Y is NH or O; X is O or S and W and W? are independently selected from the group consisting of hydrogen, —C?ONH2, —C?ONHR?, —C?ONR?R?, —C?N, and R? is C1-6 alkyl and the resultant monomer compounds. The method includes contacting a 3,4-disubstituted thiophene or selenophene or disubstituted thiophene or selenophene derivatives with a carbonyl or thiocarbonyl containing compound selected from the group consisting of ureas, thioureas, carbonate esters, thionocarbonates, thiocarbonate esters, or orthocarbonates. The monomer compounds are suitable for forming polymers for use in a wide range of electronic applications.

Abstract: The present invention relates to improved covalent coupling of two or more entities such as biomolecules, polymer compositions, organic/inorganic molecules/materials, and the like, including their combinations, through one or more novel reactive groups attached to linker groups of 2–1000 atoms length. The present invention also contemplates the use of bifunctional bridge molecules to link two or more entities, wherein the functional groups of the bridge molecules are the novel reactive groups of the present invention.

Abstract: The present invention is directed, in part, to fluorescein-based ligands for detection of metal ions, and methods of making and using the same.

Abstract: This invention provides novel stable metallic mesoporous transition metal oxide molecular sieves and methods for their production. The sieves have high electrical conductivity and may be used as solid electrolyte devices, e.g., in fuel cells, as sorbents, e.g. for hydrogen storage, and as catalysts. The invention also provides room temperature activation of dinitrogen, using the sieves as a catalyst, which permits ammonia production at room temperature.

Abstract: A selenating reagent obtained by reacting lithium aluminum hydride with selenium powder in an organic solvent. In addition, a method for preparing a selenating reagent includes reacting lithium aluminum hydride with selenium powder in an organic solvent. Also, a method of preparing a selenium-containing product includes reacting the selenating reagent, prepared as stated, with at least one second compound which may be acyl chloride.

Abstract: Novel selenophene compounds useful as anti-tumor agents are described. Preferred compounds include compounds of formula I: wherein R1 and R2 are independently selected from the group consisting of; ?H, CHO, CH2OH and CH2NH2; and X and Y are independently selected from the group consisting of Se, S, O, NCH3 and NH. Pharmaceutical compositions and a method for treating patients having tumors utilizing the disclosed selenophene compounds are also described.

Abstract: A novel class of compounds such as antagonists of the neuropeptide Y Y5 receptor, methods of making such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention or amelioration of one or more diseases associated with the neuropeptide Y Y5 receptor are disclosed.

Abstract: A process for labeling organic compounds with deuterium and tritium is described using specific catalysts.

Abstract: The invention relates to the synthesis of polymers containing self-complementary quadruple hydrogen groups by copolymerizing monomers containing a quadruple hydrogen bonding group with one or more monomers of choice. The resulting polymers show unique new characteristics due to the presence of additional physical interactions between the polymer chains that are based on multiple hydrogen bonding interactions (supramolecular interactions).

Abstract: The invention concerns novel molecules, their preparation and their uses, in particular in the field of human and veterinary medicine and cosmetics. The inventive compounds are partly fatty acid derivatives and exhibit advantageous pharmacological and cosmetic properties. The invention also concerns various uses of said compounds, the pharmaceutical compositions containing them and methods for preparing them.

Abstract: The invention relates to novel ligands of the phosphanylbenzothiophenyl-dihydroisoxazoline, phosphanyl-dihydrooxazolyl-indole and phosphanyl-dihydrooxazolyl-benzofuran type, especially compounds of formula I 1

Abstract: A compound of formula (I) wherein R2 is arylene or heterocyclene; or R and R2 together with the nitrogen atom to which they are attached form non-aromatic heterocyclene; and the other residues have various meanings, useful as pharmaceuticals, e.g. antimicrobials.

Abstract: Compounds and methods are provided for a single-pot covalent attachment of a label to nucleic acids comprising forming a covalently attachable labeling reagent for alkylating the molecule. Then, combining the covalently attachable labeling reagent with a mixture containing the molecule, under conditions wherein the labeling reagent has reactivity with the molecule thereby forming a covalent bond.

Abstract: Expanded porphyrin comprising substitutions for at least two NH groups by S, Se or Te are non-photoactive and are selective for binding G-quadruplexes characteristic of the c-MYC control region. Accordingly, these expanded porphyrins are useful to modulate the expression of genes controlled by the formation of c-MYC type G-quadruplexes, such as c-MYC itself.

Abstract: Novel selenophene compounds useful as anti-tumor agents are described.

Abstract: Dyes, containing N-benzyl-p-phenylenediamine derivatives of the general formula (I) or their physiologically compatible salts, for keratin fibers, and new N-benzyl-p-phenylenediamine derivatives.

Abstract: Detectably-labeled compounds of formula (I) wherein A,B,C,D,E,F,R,X,Y and Z have any of the meanings given in the specification, and their pharmaceutically acceptable salts, are useful in competitive assays to assay for the presence of 2 receptors. Also disclosed are pharmaceutical compositions containing such a compound of formula (I), methods for their use and intermediates useful for preparing such compounds of formula (I).

Abstract: The present invention relates to alkylenedioxythiophenes of the formula I having urethane-containing side groups 1

Abstract: A method for synthesizing Salacinol, its stereoisomers, and non-naturally occurring selenium and nitrogen analogues thereof having the general formula (I): 1

Abstract: The present invention relates to a method and catalysts for the stereoselective addition of a nucleophile to a reactive &pgr;-bond of a substrate. The chiral, non-racemic catalysts of the present invention constitute the first examples of catalysts for nucleophilic additions that comprise a main-group metal and a tri- or tetra-dentate ligand.

Abstract: Novel selenophene compounds useful as anti-tumor agents are described. Preferred compounds include compounds of formula I: wherein R1 and R2 are independently selected from the group consisting of; H, CHO, CH2OH and CH2NH2; and X and Y are independently selected from the group consisting of Se, S, O, NCH3 and NH. Pharmaceutical compositions and a method for treating patients having tumors utilizing the disclosed selenophene compounds are also described.

Abstract: The present invention relates to derivatives of 4-(Thio- or Selenoxanthene-9-ylidene)-piperidine or acridine and pharmaceutically acceptable salts thereof, use of these compounds as a medicament and for the manufacture of a medicament for treatment of a disease state which can be alleviated by treatment with a 5-HT2B antagonist.

Abstract: A process for preparing a heteroaromatic compound having a heteroaromatic nucleus substituted with one or more ether groups comprising the step of: condensing at least one hydroxy-group of a compound having said heteroaromatic nucleus, said at least one hydroxy group (—OH) being substituted at &agr;- or &bgr;-positions with respect to a heteroatom of said heteroaromatic nucleus, with an alcohol containing one or more primary or secondary alcohol groups, optionally substituted with nitro, amide, ester, halogen, cyano or (hetero)aromatic groups, using the redox couple of a triaryl- or trialkylphosphine and an azodioxo-compound at a temperature between −40° C. and 160° C.

Abstract: A process for preparing novel 1,3-selanazolin derivatives represented by chemical formula 1 at high yield. This process includes a step of reacting a selenourea and an &agr;-haloacyl halide in a solvent and in the presence of a catalyst.

Abstract: Process for the polymerization of unsaturated vinyl and/or vinylidene monomers which comprises reacting one or more monomers in the presence of heterocyclic initiators having a nitrogen atom bound to an oxygen atom at a temperature ranging from 100 to 130° C.

Abstract: The present invention has identified thiaprophyrin, selenaporphyrin, and carotenoid porphyrin compounds that bind the G-quadruplex formed by the folding of single-stranded human telomeric DNA. These compounds have been shown to be effective telomerase and c-myc inhibitors and are contemplated to be useful in developing cancer treatments.

Abstract: The invention relates to a process for the preparation of heterocycles, characterised in that the following components:

Abstract: Provided are processes for synthesizing structurally diverse pyruvate-derived compounds using a parallel approach on a solid phase support. Examples of such a solid phase support include resins which have also been used in solid phase peptide synthesis.

Abstract: An electron accepting monomer having the formula: 1